Global Gastric Electrical Stimulation GES Market Size By Type (Low Frequency GES Device, High Frequency GES Device), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Gastric Electrical Stimulation (GES) Market was valued at USD 445 million in 2023 and is projected to reach USD 860 million by 2031, growing at a CAGR of 8.4% during the forecast period (2023–2031). GES devices, which apply electrical pulses to the stomach wall, are increasingly being adopted for treating gastroparesis, obesity, and other gastrointestinal motility disorders. Market growth is driven by rising prevalence of gastric disorders, increasing acceptance of minimally invasive treatment techniques, and ongoing innovations in neuromodulation technologies. The rising geriatric population and growing healthcare expenditure are further contributing to the expanding adoption of GES devices globally.

Drivers:

1. Increasing Prevalence of Gastroparesis and Obesity:

Chronic conditions such as diabetes-related gastroparesis and obesity are seeing significant global rise. GES provides an effective alternative for patients unresponsive to pharmacologic treatments, thus expanding its clinical adoption.

2. Technological Advancements in GES Devices:

Innovation in device miniaturization, programmability, and battery life is enhancing the effectiveness and patient compliance. Integration with smart monitoring systems and MRI-compatible devices is driving broader clinical usage.

3. Rising Preference for Minimally Invasive Procedures:

As patient preference shifts towards minimally invasive and outpatient procedures, GES implants are being increasingly accepted, offering benefits such as shorter hospital stays and faster recovery.

Restraints:

1. High Procedure and Device Costs:

GES implantation involves significant expenses, making it less accessible in low-income regions. Limited reimbursement policies in several countries further restrain market growth.

2. Limited Clinical Awareness and Trained Professionals:

Many healthcare providers remain unaware of GES as a treatment option, particularly outside major metropolitan centers. This lack of awareness and surgical expertise limits adoption rates.

Opportunity:

1. Expanding Indications Beyond Gastroparesis:

Clinical trials and regulatory advancements are exploring GES for conditions such as functional dyspepsia and chronic nausea. These expanding indications provide untapped opportunities for market players.

2. Emerging Markets with Increasing Healthcare Investment:

Regions such as Asia-Pacific and Latin America are witnessing increased healthcare infrastructure development and rising diagnosis rates of GI disorders, creating fertile ground for market expansion.

Market by System Type Insights:

Based on system type, the Implantable Gastric Electrical Stimulator segment dominated the market in 2023. These devices are favored due to their long-term efficacy, adjustable settings, and integration with external controllers. Non-invasive and temporary stimulation devices are emerging, but currently hold a minor market share.

Market by End-use Insights:

Hospitals held the largest market share in 2023, accounting for over 60% of revenue. The segment benefits from reimbursement availability, access to trained surgeons, and postoperative monitoring capabilities. However, ambulatory surgical centers (ASCs) are expected to witness the highest growth rate due to shorter procedural times and growing acceptance for outpatient procedures.

Market by Regional Insights:

North America led the global GES market in 2023, driven by robust reimbursement frameworks, high healthcare spending, and early adoption of neuromodulation devices. Europe follows closely due to increasing adoption of GES for diabetic gastroparesis. The Asia-Pacific region is anticipated to grow at the fastest rate, owing to increasing obesity rates, improving medical infrastructure, and rising awareness.

Competitive Scenario:

Key players in the GES market include Medtronic plc, IntraPace Inc., ReShape Lifesciences Inc., LivaNova PLC, and EnteroMedics. These companies are actively pursuing FDA approvals, strategic collaborations, and clinical trials to expand indications and geographic reach.

Key Developments:

In 2023, Medtronic launched a next-gen implantable stimulator with wireless programming features.

ReShape Lifesciences received expanded regulatory clearance in Europe for their anti-obesity GES device.

LivaNova initiated a multi-center trial to assess GES for treatment-resistant nausea in diabetic patients in 2024.

Scope of Work – Global Gastric Electrical Stimulation (GES) Market

Report Metric Details

Market Size (2023) USD 445 million

Projected Market Size (2031) USD 860 million

CAGR (2023–2031) 8.4%

Market Segments By System Type, End-use, Region

Growth Drivers Rising gastroparesis & obesity cases, technological advancements

Opportunities Indication expansion, growth in emerging markets

FAQs:

1) What is the current market size of the Global Gastric Electrical Stimulation (GES) Market?

The market was valued at USD 445 million in 2023.

2) What is the major growth driver of the Global Gastric Electrical Stimulation (GES) Market?

Rising prevalence of gastroparesis and obesity, along with demand for minimally invasive solutions, is the primary growth driver.

3) Which is the largest region during the forecast period in the Global Gastric Electrical Stimulation (GES) Market?

North America is the largest region, supported by advanced healthcare infrastructure and high treatment adoption rates.

4) Which segment accounted for the largest market share in Global Gastric Electrical Stimulation (GES) Market?

The Implantable Gastric Electrical Stimulator segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Gastric Electrical Stimulation (GES) Market?

Key players include Medtronic plc, IntraPace Inc., ReShape Lifesciences Inc., LivaNova PLC, and EnteroMedics.